share_log

中國中藥：聯合公告 (1) 要約人根據公司條例第673條通過計劃安排的方式將 中國中藥控股有限公司私有化之附先決條件之建議 (2) 建議撤銷中國中藥控股有限公司的上市地位 (3) 成立獨立董事委員會 (4) 恢復中國中藥控股有限公司股份買賣

TRAD CHI MED: JOINT ANNOUNCEMENT (1) PRE-CONDITIONAL PROPOSAL TO PRIVATISE CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED BY THE OFFEROR BY WAY OF A SCHEME OF ARRANGEMENT UNDER SECTION 673 OF THE COMPANIES ORDINANCE (2) PROPOSED WITHDRAWAL OF LIST

香港交易所 ·  Feb 21 07:07
Summary by Moomoo AI
中國中藥控股有限公司（簡稱「中國中藥」）於2024年2月9日宣布，將通過計劃安排方式私有化，並撤銷在香港聯合交易所有限公司（香港聯交所）的上市地位。此次私有化由國藥集團共裕有限公司（要約人）提出，並已成立獨立董事委員會。中信證券（香港）有限公司作為要約人的財務顧問。計劃股份將以每股4.6港元的價格註銷，此價格較最後交易日收市價溢價約34.11%，並較過去一段時間的平均收市價有顯著溢價。控股股東計劃股份將以要約人股份作為註銷代價。計劃的實施須經股東特別大會批准，並符合相關法律及監管要求。股份自2024年2月8日起暫停交易，並於2月22日恢復買賣。此外，若計劃未能獲批准或建議失效，股份在香港聯交所的上市地位將不會被撤銷。
中國中藥控股有限公司（簡稱「中國中藥」）於2024年2月9日宣布，將通過計劃安排方式私有化，並撤銷在香港聯合交易所有限公司（香港聯交所）的上市地位。此次私有化由國藥集團共裕有限公司（要約人）提出，並已成立獨立董事委員會。中信證券（香港）有限公司作為要約人的財務顧問。計劃股份將以每股4.6港元的價格註銷，此價格較最後交易日收市價溢價約34.11%，並較過去一段時間的平均收市價有顯著溢價。控股股東計劃股份將以要約人股份作為註銷代價。計劃的實施須經股東特別大會批准，並符合相關法律及監管要求。股份自2024年2月8日起暫停交易，並於2月22日恢復買賣。此外，若計劃未能獲批准或建議失效，股份在香港聯交所的上市地位將不會被撤銷。
CHINA PHARMACEUTICALS HOLDINGS LIMITED (“CHINESE MEDICINE”) ANNOUNCED ON 9 FEBRUARY 2024 THAT IT WILL BE PRIVATIZED THROUGH A PLANNED ARRANGEMENT AND REVOKED THE LISTING STATUS OF THE HONG KONG UNITED STOCK EXCHANGE LIMITED (HKEX). The privatization was proposed by Kongyu Yue Co., Ltd. (Contracting Party), and an independent Board of Directors has been established. CITIC SECURITIES (HONG KONG) LIMITED AS FINANCIAL ADVISOR TO THE CONTRACTOR. The plan shares will be written off at a price of HK$4.6 per share, which is approximately 34.11% above the closing market price of the last transaction and a significant premium over the past period of time. The controlling shareholder plans shares to be written off at the purchaser's share as a write-off price. The implementation...Show More
CHINA PHARMACEUTICALS HOLDINGS LIMITED (“CHINESE MEDICINE”) ANNOUNCED ON 9 FEBRUARY 2024 THAT IT WILL BE PRIVATIZED THROUGH A PLANNED ARRANGEMENT AND REVOKED THE LISTING STATUS OF THE HONG KONG UNITED STOCK EXCHANGE LIMITED (HKEX). The privatization was proposed by Kongyu Yue Co., Ltd. (Contracting Party), and an independent Board of Directors has been established. CITIC SECURITIES (HONG KONG) LIMITED AS FINANCIAL ADVISOR TO THE CONTRACTOR. The plan shares will be written off at a price of HK$4.6 per share, which is approximately 34.11% above the closing market price of the last transaction and a significant premium over the past period of time. The controlling shareholder plans shares to be written off at the purchaser's share as a write-off price. The implementation of the Plan is subject to the approval of the Extraordinary General Meeting and in compliance with the relevant legal and regulatory requirements. The shares were suspended from 8 February 2024 and trading resumed on 22 February. In addition, the listed position of the shares on the HKEx will not be revoked if the scheme is not approved or the proposal is invalidated.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more